Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow CNS Pharmaceuticals, Inc.

Get SEC filing alerts via email and in your feed for CNS Pharmaceuticals, Inc.

CNSP

CNS Pharmaceuticals, Inc.

About CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals is a clinical-stage biotech focused on developing innovative treatments for brain and CNS tumors. Its key products, Berubicin and TPI 287, aim to cross the blood-brain barrier to target glioblastoma and other cancers. The company leverages orphan drug status and regulatory designations to advance therapies addressing unmet medical needs in oncology markets worldwide. It operates through licensing, clinical trials, and strategic collaborations.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from CNS Pharmaceuticals, Inc.

1
1
CNS Pharmaceuticals, Inc. CNS Pharmaceuticals Reports $4.9 Million Net Loss and Announces New Corporate Strategy

Via official filing (AI summary) | 21 days ago | 0 comments

2
1
CNS Pharmaceuticals, Inc. CNS Pharmaceuticals Reports $15.9 Million Net Loss for Fiscal Year 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
CNS Pharmaceuticals, Inc. CNS Pharmaceuticals Reports Decreased Net Losses and Increased Cash Reserves for Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
CNS Pharmaceuticals, Inc. CNS Pharmaceuticals Reports Financial Developments and Clinical Trial Progress for Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
CNS Pharmaceuticals, Inc. CNS Pharmaceuticals Reports Q1 2025 Financial Results with Increased Net Loss and Improved Cash Reserves

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
CNS Pharmaceuticals, Inc. CNS Pharmaceuticals Reports Significant Financial Developments, Raises Capital, and Advances Pipeline in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments